Search for an Optimal Efficacy-To-Safety Ratio for Anti-Platelet Therapy of Ischemic Heart Disease

Medical Council
doi 10.21518/2079-701x-2018-5-34-40
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Remedium, Ltd.

Related search

Kawasaki Disease – Options for Anti-Platelet Therapy

Austin Journal of Pharmacology and Therapeutics
2017English

Choice of Optimal Proton Pump Inhibitor for Patients With Ischemic Heart Disease Who Require Dual Antiplatelet Therapy

HYPERTENSION
2018English

Mechanistic Molecular Imaging of Cardiac Cell Therapy for Ischemic Heart Disease

American Journal of Physiology - Heart and Circulatory Physiology
Cardiovascular MedicinePhysiologyCardiology
2013English

Platelet Thromboxane A2 Synthetizing Activity in Ischemic Heart Disease

Blood & Vessel
1983English

Role of Coronary Vasoconstriction in Ischemic Heart Disease and Search for Novel Therapeutic Targets

Circulation Journal
MedicineCardiovascular MedicineCardiology
2009English

Efficacy and Safety of Trimetazidine (Сarmetadin) in the Comprehensive Treatment of Patients With Ischemic Heart Disease and Chronic Heart Failure

HYPERTENSION
2018English

Role of Optimal Medication Given to Patients With Hypertension and Ischemic Heart Disease Prior to an Acute Coronary Syndrome

Heart International
Cardiovascular MedicineCardiology
2017English

Efficacy and Safety of Goreisan for Chronic Heart Failure Patients With Chronic Kidney Disease

Kampo Medicine
2019English

Efficacy and Safety of Inhaled Nitric Oxide Using Nasal High-Flow Oxygen Therapy After Pediatric Cardiac Surgery for Congenital Heart Disease

Journal of the Japanese Society of Intensive Care Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy